3106269128

Connor, J.H., and Lyles, D.S. (2002). Vesicular Stomatitis Virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1. J. Virol. 76, 10177-10187.

Cureton, D.K, Massol, R.H., Saffarian, S., Kirchhausen, T.L., and Whelan, S.P.J. (2009). Vesicular Stomatitis Virus enters cells through vesicles incompletely coated with clathrin that depend upon actin for intemalization. PLoS Pathog. 5, e 1000394.

Dancho, B., McKenzie, M.O., Connor, J.H., and Lyles, D.S. (2009). Vesicular stomatitis virus matrix protein mutations that affect association with host membranes and viral nucleocapsids. The Journal of Biological Chemistry 284, 4500-4509.

Desforges, M., Charron, J., Bćrard, S., Beausoleil, S., Stojdl, D.F., Despars, G., Laverdiere, B., Bell, J.C., Talbot, P.J., Stanners, C.P., and Poliquin, L. (2001). DifTerent host-celi shutoff strategies related to the matrix protein lead to persistance of vesicular stomatitis virus mutants on fibroblast cells. Virus Res. 76, 87-102.

Desforges, M., Despars, G., Berard, S., Gosselin, M., McKenzie, M.O., Lyles, D.S., Talbot, P.J., and Poliąuin, L. (2002). Matrix protein mutations contribute to inefficient induction of apoptosis leading to persistent infection of human neural cells by Vesicular Stomatitis Virus. Virology 295, 63-73.

Dock, G. (1904). Influence of complicating diseases upon leukemia. Am. J. Med. Sci. 127, 563-592.

Doronin, K., Shashkova, E.V., May, S.M., Hofherr, S.E., and Barry, M.A. (2009). Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic Adenovirus Hum. Gene Ther. 20, 975-988.

Francoeur, A.M., Poliquin, L., and Stanners, C.P. (1987). The isolation of interferon-inducmg mutants of vesicular stomatitis virus with altered viral P function for the inhibition of total protein synthesis. Virology 160, 236-245.

Fu, X., and Zhang, X. (2002) Potent systemie antitumor activity from an oncolytic Herpes Simplex Virus of syncytial phenotype. Cancer Res. 62, 2306-2312.

Fulci, G., Breymann, L., Gianni, D., Kurozomi, K., Rhee, S.S., Yu, J., Kaur, B., Louis, D.N., Weissleder, R., Caligiuri, M.A., and Chiocca, E.A. (2006). Cyclophosphamide